RPG Life Sciences Ltd on Friday (October 17) reported a sharp rise in net profit for the second quarter of FY26 at ₹37 crore, compared with ₹4.2 crore in the same period last year. The company’s revenue grew 5.5% year-on-year to ₹182 crore, against ₹172 crore a year ago.However, operating performance moderated during the quarter, with EBITDA declining 15% to ₹39 crore from ₹46 crore in the year-ago period. The EBITDA margin fell to 21.5%, compared with 26.5% in the corresponding quarter of the previous fiscal.Also Read: RPG Life targets ₹100 crore sales from pain relief drug Naprosyn over the next two years
Ashok Nair, Managing Director, RPG Life Sciences, said, “In Q2, we have further strengthened our growth trajectory, driven by disciplined execution and a clear strategic focus. Our domestic formulations business is delivering market-beating performance with a growth of 13.5% in H1 FY26 versus the Indian Pharma Market, which recorded a growth of 7.4% in H1.Our transformation agenda is anchored in a legacy of quality and focused on enhancing patient outcomes. We are making steady progress in our International Formulations and API business, supported by new customer acquisitions, expansion into both emerging and regulated markets, and the launch of molecules that enhance our therapeutic footprint.”Shares of RPG Life Sciences Ltd ended at ₹2,295.00, down by ₹11.00, or 0.48%, on the BSE.Also Read: RPG Life Sciences eyes ₹1,000 crore turnover, continued margin expansion
